Tuesday, May 25, 2021 8:39:11 PM
Misiu,
I sincerely appreciate your effort to address these situations with Dr. Pourhassan. I suspect he realizes a lot is riding on these trials. I hope he looks at your advice and considers it carefully. I hope he also realizes that your comments are not argumentative but totally supportive. You, I, and many others want him to succeed in making Leronlimab accessible for all.
Sometimes, when one is under duress, as Nader is, it's possible to mis-identify who's wearing the "white Hats" (good Guys and gals). I hope he noticed your Very prominent "ten-gallon Texas-style White as white-can-be hat!"
Thank YOU for all you do!
Also I must apologize. I thought BBNCT was the one "meeting with" Sen Clyburn. I didn't realize it was you, thus did not get a chance to send you the background info I developed on Clyburn. Fortunately, I know the dialog was in excellent hands with or without the extra info.
FWIW The CytoDyn bibliography has grown, but I'm hesitant to publish it again. I'm discovering some key pieces of information are now "blocked" and I don't want to give the blockers a "road map" to everything. If you have cause to need it let me know and we'll find a way to "transfer it."
With regards
I sincerely appreciate your effort to address these situations with Dr. Pourhassan. I suspect he realizes a lot is riding on these trials. I hope he looks at your advice and considers it carefully. I hope he also realizes that your comments are not argumentative but totally supportive. You, I, and many others want him to succeed in making Leronlimab accessible for all.
Sometimes, when one is under duress, as Nader is, it's possible to mis-identify who's wearing the "white Hats" (good Guys and gals). I hope he noticed your Very prominent "ten-gallon Texas-style White as white-can-be hat!"
Thank YOU for all you do!
Also I must apologize. I thought BBNCT was the one "meeting with" Sen Clyburn. I didn't realize it was you, thus did not get a chance to send you the background info I developed on Clyburn. Fortunately, I know the dialog was in excellent hands with or without the extra info.
FWIW The CytoDyn bibliography has grown, but I'm hesitant to publish it again. I'm discovering some key pieces of information are now "blocked" and I don't want to give the blockers a "road map" to everything. If you have cause to need it let me know and we'll find a way to "transfer it."
With regards
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
